AB0218 RHEUMATOID ARTHRITIS OUTCOMES: A MULTICENTRE CROSS-SECTIONAL STUDY OF PATIENTS IN IRELAND (CONTEXT-RA)

Background Despite increasing treatment options for RA, many patients still do not appear to achieve remission, especially in more established disease. [1] Objectives To evaluate disease outcomes and quality of life (QoL) DMARD treated with RA clinical remission (CR) routine Irish rheumatology clinics vs those residual activity. Methods A multicentre, cross-sectional study a 9-month recruitment period (Mar-Nov 2021). Demographics, activity, patient reported outcomes, comorbidities, workability & healthcare resource utilisation (HRU) data were collected. Patients on stable dose any (> 3 months) classified according activity state as follows: Responder group 1 (RG1) CR (CDAI≤2.8) 2 (RG2) CR/ Low Disease Activity (LDA) (CDAI>2.8 -10) Non-responders (NR) moderate/high (CDAI>10) Results 130 recruited (Table 1). 69% female, mean age 60.1 yrs duration 11.5 yrs. There was no significant difference seropositivity between responder non-responder groups (~75% RF+, ~69% ACPA+), advanced therapy (biologic/targeted synthetic DMARDs), primarily TNFi’s. 26% CR, 32% LDA 42% NR. Significant differences QoL-primary endpoint noted CR/LDA NR group. The QoL index score (EQ5D-5L) alone, suggest is considerably higher compared even LDA. Joint pain (VAS), fatigue (FACIT-F) function (HAQ-DI) scores all yielded strong negative correlations, indicating that had significantly better than MDA/HDA (Figure similar pattern seen amongst LDA, although significance achieved. In addition, impaired productivity regarding ability work perform regular ‘non-work’ activities. Comorbidities common, affecting over 90% the 74% CR. proportions cardiac, gastrointestinal, psychiatric vascular disorders CR/LDA. With respect HRU, required medical visits both non-RA reasons Of 54 MDA/HDA, found there plan add or switch DMARD, only patients. Table 1. Patient Characteristics RG1 N=34 RG N=76 N=54 Age Mean (SD), 57.1 (12.91) 57.6 (13.13) 63.7 (13.00) Female, N (%) 23 (67.6) 51 (67.1) 38 (70.4) Duration disease, yrs, (SD) 12.1 (10.5) 11.2 (11.4) 11.3 (11.02) Comorbidities, n 25 (73.5) 36 (85.7) 49 (90.7) Employed^, 19 (55.8) 37 (48.6) 11 (20.3) Employment sick leaves due RA^*, 0.3 (0.58) (0.57) 0.6 (1.21) Smoking status: Never smoked, 17 (50.0) 35 (46.1) 18 (33.3) Alcohol Units, 4.0 (5.98) 3.3 (6.31) 3.8 (6.05) (CDAI score) 1.21 (0.883) 4.06 (3.088) 19.46 (11.162) ^ either full part time employment *Sick leave past 6 months Conclusion Overall, these support treat-to-target approach striving important but additionally achieving relatively low % documented ‘action plan’, suggests improved approaches shared decision making are warranted yet at agreed target. Reference Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas Burmester G, Combe B, Cutolo M, de Wit Dougados M: Treating rheumatoid arthritis target: recommendations an international task force. Ann Rheum Dis. 2010, 69: 631-637. Acknowledgements authors wish thank O4 Research management site assistance design case report form, management, preparation report. financial this provided by AbbVie per contract. acknowledge Ms Phil Gallagher, Hannah Darcy, Denise Breen, Dr Diana Gheta UCC CRF Cork Waterford, recruiting study; Disclosure Interests Grainne Murphy Consultant of: Has served consultant conduct CONTExT-RA has received research funding from AbbVie., David Kane CONTeXT-RA study, have Killian O’Rourke Served AbbVie, Grant/research from: educational bursaries travel national conferences MSD, UCB, Roche, Novartis Jannsen”., Claire Sheehy “I AbbVie; I advisory board Janssen.”, Finbar Barry O’Shea Richard Conway Speakers bureau: Janssen, Sanofi, Abbvie, Pfizer, Novartis, Galapagos, Douglas Veale Shareholder shareholder Health Beacon, Bureau BMS, Celgene, Gilead, UCB., AbbVie. Consultant/Advisor Actelion, Regeneron/Sanofi, Grant/Research Amgen, Eli Lilly, Angela Camon Advisory boards Roche ad Consilient education attend Nordic Deirdre Moran Shares Employee